ClinicalTrials.gov
public full text
Public Domain
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clomiphene Citrate for Treatment of Acromegaly#1152631
- Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly#856087
- Canadian Pegvisomant Compassionate Study In Acromegalic Patients#830357
- Prediction of Tumor Shrinkage in Acromegaly#1111360
- Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly#879715
Record · ID 980992
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive